What the Delta variant could mean for the Pfizer vaccine

A vaccine
(Image credit: JAVIER TORRES/AFP via Getty Images)

As the Delta variant of COVID-19 makes its way across the globe, a new report from Israeli website Ynet has some good news about the Pfizer-BioNTech vaccine — and some bad. First, the good news: Data from the Israel Health Ministry find the vaccine holds up well against the variant when it comes to hospitalizations and serious illness, with an efficacy rate of 93 percent according to data from June 6 to July 3, when the Delta variant really began to take hold, Bloomberg reports. That's down from 98.2 percent compared to the variants that came before, but still very good.

The bad news is the data appear to indicate a significant drop in efficacy when it comes to the Pfizer vaccine preventing infection overall. Between May 2 and June 5, the vaccine had a 94.3 percent efficacy rate at preventing infection, Bloomberg explains. That rate dropped to 64 percent in the month that followed.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us